Clopidogrel versus Aspirin after Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients Undergoing Drug Eluting Stenting
Background and Objectives There is a paucity of data regarding the benefit of clopidogrel monotherapy after dual antiplatelet therapy (DAPT) in patients treated with drug eluting stents (DES) This study compared outcome between clopidogrel versus aspirin as monotherapy after DES for acute myocardial infarction (MI) Methods From Korea Acute Myocardial Infarction Registry National Institute of Health database, 1,819 patients treated with DES who were switched to monotherapy with clopidogrel (n=534) or aspirin (n=1,285) after uneventful 12 month DAPT were analyzed. The primary endpoint was net adverse clinical events (NACE) defined as a composite of death from any cause, MI, repeat percutaneous coronary intervention (PCI) stent thrombosis, ischemic stroke, or major bleeding during the period from 12 to 24 months. Results After adjustment using inverse probability of treatment weighting, patients who received clopidogrel, compared with those treated with aspirin, had a similar incidence of NACE (0.7% and 0.7% hazard ratio, 1.06; 95% confidence interval, 0.31 3.60; p=0.923) The 2 groups had similar rates of death from any cause (0.1% in each group, p=0.789) MI (0.3% and 0.1% respectively; p=0.226) repeat PCI (0.1% and 0.3% respectively; p=0.548) stent thrombosis (0.1% and 0% respectively; p=0.121) major bleeding (0.2% in each group, p=0.974) and major adverse cardiovascular and cerebrovascular events (0.5% in each group, p=0.924) Conclusions Monotherapy with clopidogrel, compared to aspirin, after DAPT showed similar clinical outcomes in patients with acute MI treated with DES.
Korean circulation journal